Citations (0)
Keep up to date with the latest research on this topic with citation updates for this article.
Lung Cancer: Targets and Therapy
Volume 13, 2022 - Issue
Commentary
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
Shannon S Zhang1 University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USA
https://orcid.org/0000-0003-3157-5598
https://orcid.org/0000-0003-3157-5598 & Sai-Hong Ignatius Ou1 University of California Irvine School of Medicine, Department of Medicine, Orange, CA, USA;2 Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence[email protected]
https://orcid.org/0000-0002-1764-4975
https://orcid.org/0000-0002-1764-4975